Opendata, web and dolomites

RITA-MI

Rituximab in Acute Myocardial Infarction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RITA-MI project word cloud

Explore the words cloud of the RITA-MI project. It provides you a very rough idea of what is the project "RITA-MI" about.

med    lymphocytes    acute    infarction    ultimate    benefit    successful    al    cvd    first    erc    forget    series    site    reducing    therapies    25    mortality    cell    re    breaking    instrumental    mab    validated    zouggari    scheme    injury    reduces    monoclonal    risk    selective    therapy    depletes    myocardial    patients    cd20    30    function    efficacy    diseases    trial    disease    infusion    substantially    infarct    2013    safe    rita    purposing    heart    morbidity    interestingly    size    mobilisation    ground    dose    ccl7    orchestration    reduce    hypothesis    monocytes    cv    limit    et    cells    fire    starting    grant    group    chemokine    events    ischemic    readily    co    followed    therapeutic    mi    excess    correspond    proof    immune    discovery    considerable    pursued    improves    single    morbidities    recruitment    translate    rapid    death    cardiovascular    burden    clinical    antibody    stemi    inflammatory    mature    rituximab    intravenous    nat    circulating    initiation    ineffective    drug   

Project "RITA-MI" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 149˙402 €
 EC max contribution 149˙402 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 15˙266.00
2    PAPWORTH HOSPITAL NHS FOUNDATION TRUST UK (CAMBRIDGE) participant 134˙136.00

Map

 Project objective

Cardiovascular diseases (CVD) represent a major cause of morbidity and mortality. The best current therapy reduces CV risk by only 25-30% and remains ineffective in reducing the excess risk associated with several co-morbidities. Therefore, there is considerable need for new therapies to limit the burden of CVD. Based on a current ERC Starting Grant project, the applicant’s group proposed and validated the concept that mature B lymphocytes are instrumental in the orchestration of the inflammatory response after ischemic myocardial injury, in part through production of CCL7 chemokine and mobilisation/recruitment of inflammatory monocytes to the infarction site (Zouggari Y et al., Nat Med 2013). Our goal now is to translate this ground-breaking discovery and novel therapeutic concept into benefit for patients. The overall objective of the RITA-MI project is to develop a new and cost-effective therapy for patients with acute myocardial infarction (MI) based on selective targeting of the B cell immune response, with the ultimate aim to substantially reduce the high risk of death and major cardiovascular events associated with the disease. Interestingly, the drug, CD20 monoclonal antibody (mAb) rituximab, is readily available for testing in a re-purposing scheme, allowing for rapid initiation of this proof-of-concept clinical trial. Working Hypothesis: A single infusion of rituximab at the acute phase of MI is safe, substantially depletes circulating B cells, and has the potential to limit infarction size and improves myocardial heart function. Overall objective: Does a ‘fire and forget’ approach with rituximab (a single intravenous infusion) reduce infarct size and/or improve heart function in patients with acute STEMI? The overall aim will be pursued through a series of specific objectives, which will correspond to a first step of a dose-finding proof-of-concept study (the present RITA-MI project), followed (if successful) by a phase II clinical efficacy trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RITA-MI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RITA-MI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  

KEYNESGROWTH (2020)

Economic Fluctuations, Productivity Growth and Stabilization Policies: A Keynesian Growth Perspective

Read More  

DimorphicCircuits (2019)

Elucidating the development of sexually-dimorphic circuits: from molecular mechanisms to synapses and behavior

Read More